Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consistency of V260 (RotaTeq) Lots in Healthy Infants
NCT00092456Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2003
- Primary completion
- Aug 2004
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of rotavirus vaccine, live, oral, pentavalent in rotavirus infection (4 arms), sponsored by Merck & Co. Primary endpoint: Serum Neutralizing Antibodies Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8]. Started May 2003; status: completed.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotavirus infection
Beyond the preview
Go deeper on NCT00092456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092456.